Millennium Management LLC Invests $28,000 in Vistagen Therapeutics Inc (VTGN) Stock

Millennium Management LLC acquired a new position in shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) during the fourth quarter, HoldingsChannel reports. The fund acquired 18,623 shares of the company’s stock, valued at approximately $28,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. D.A. Davidson & CO. lifted its holdings in Vistagen Therapeutics by 22.9% during the 4th quarter. D.A. Davidson & CO. now owns 94,000 shares of the company’s stock worth $141,000 after purchasing an additional 17,500 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Vistagen Therapeutics by 13.0% during the 4th quarter. Geode Capital Management LLC now owns 154,457 shares of the company’s stock worth $231,000 after purchasing an additional 17,721 shares in the last quarter. Northern Trust Corp lifted its holdings in Vistagen Therapeutics by 168.6% during the 4th quarter. Northern Trust Corp now owns 69,642 shares of the company’s stock worth $104,000 after purchasing an additional 43,714 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Vistagen Therapeutics by 42.7% in the 3rd quarter. Vanguard Group Inc. now owns 257,465 shares of the company’s stock valued at $373,000 after acquiring an additional 77,090 shares in the last quarter. Finally, Vanguard Group Inc raised its holdings in shares of Vistagen Therapeutics by 42.7% in the 3rd quarter. Vanguard Group Inc now owns 257,465 shares of the company’s stock valued at $373,000 after acquiring an additional 77,090 shares in the last quarter. 6.87% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have weighed in on the company. Zacks Investment Research cut Vistagen Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 11th. Maxim Group reaffirmed a “buy” rating and issued a $6.00 price target on shares of Vistagen Therapeutics in a report on Wednesday, March 6th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $8.30.

NASDAQ:VTGN opened at $0.76 on Friday. Vistagen Therapeutics Inc has a twelve month low of $0.52 and a twelve month high of $2.44. The stock has a market capitalization of $31.75 million, a price-to-earnings ratio of -0.68 and a beta of -0.42.

COPYRIGHT VIOLATION WARNING: “Millennium Management LLC Invests $28,000 in Vistagen Therapeutics Inc (VTGN) Stock” was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/19/millennium-management-llc-invests-28000-in-vistagen-therapeutics-inc-vtgn-stock.html.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Story: Are sell-side analysts objective?

Want to see what other hedge funds are holding VTGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vistagen Therapeutics Inc (NASDAQ:VTGN).

Institutional Ownership by Quarter for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.